Shares of Aratana Therapeutics Inc (NASDAQ:PETX) have been assigned a consensus rating of “Hold” from the eight analysts that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $4.73.

A number of equities analysts have recently commented on PETX shares. TheStreet cut Aratana Therapeutics from a “c-” rating to a “d+” rating in a report on Monday, March 4th. HC Wainwright cut Aratana Therapeutics from a “buy” rating to a “neutral” rating and set a $5.00 target price for the company. in a report on Friday, April 26th. Zacks Investment Research cut Aratana Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, March 14th. William Blair cut Aratana Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.14 target price for the company. in a report on Thursday, January 24th. Finally, Credit Suisse Group cut Aratana Therapeutics from an “outperform” rating to a “neutral” rating and set a $4.76 target price for the company. in a report on Tuesday, April 30th.

Several hedge funds have recently modified their holdings of PETX. Truvestments Capital LLC bought a new stake in shares of Aratana Therapeutics during the 1st quarter worth approximately $25,000. Toth Financial Advisory Corp bought a new stake in shares of Aratana Therapeutics during the 1st quarter worth approximately $30,000. BNP Paribas Arbitrage SA lifted its stake in shares of Aratana Therapeutics by 64,346.7% during the 1st quarter. BNP Paribas Arbitrage SA now owns 9,667 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 9,652 shares during the last quarter. Adams Asset Advisors LLC bought a new stake in shares of Aratana Therapeutics during the 1st quarter worth approximately $36,000. Finally, Highland Private Wealth Management lifted its stake in shares of Aratana Therapeutics by 35.0% during the 1st quarter. Highland Private Wealth Management now owns 13,500 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 3,500 shares during the last quarter. 66.83% of the stock is owned by hedge funds and other institutional investors.

Shares of Aratana Therapeutics stock opened at $4.81 on Monday. The company has a market capitalization of $237.50 million, a PE ratio of -15.03 and a beta of 1.49. Aratana Therapeutics has a one year low of $3.30 and a one year high of $7.16.

Aratana Therapeutics (NASDAQ:PETX) last announced its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.04). The company had revenue of $7.36 million during the quarter, compared to analysts’ expectations of $6.98 million. Aratana Therapeutics had a negative return on equity of 12.99% and a negative net margin of 33.47%. As a group, research analysts forecast that Aratana Therapeutics will post -0.34 earnings per share for the current year.

About Aratana Therapeutics

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States. Its product portfolio includes small molecule therapeutics and therapeutic candidates. The company markets NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs; ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States.

Further Reading: How much money do you need to begin day trading?

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.